Revimmune Overview
- Founded
-
2006
- Status
-
Acquired/Merged
- Employees
-
2
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
Revimmune General Information
Description
Developer of therapies for autoimmune diseases. The Company's lead antineoplastic technology employs a bioengineered poliovirus construct and targets cancerous central nervous cells with great specificity recombinant poliovirus therapy has the potential to significantly reduce or eliminate current chemotherapy side-effects while completely destroying abnormal cancerous tissue.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Acquirer
Accentia Biopharmaceuticals
Primary Office
- 324 South Hyde Park Avenue
- Suite 350
- Tampa, FL 33606
- United States
Revimmune Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Revimmune Executive Team (3)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Frank O'Donnell | Director & Officer | ||
| Richard Jones | Co-Founder | ||
| Robert Brodsky | Co-Founder |
Revimmune Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Revimmune Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|